Fibrocell Science Inc., of Exton, Pa., will collaborate with the University of California, Los Angeles to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity. The company said that the collaboration is designed to set the stage for potential future diagnostic or treatments based on each person's own cells for illnesses such as Parkinson's disease, diabetes and heart disease.